

HR 3520

Stem Cell Therapeutic and Research Reauthorization Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 26, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 27, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/3520>

Sponsor

Name: Rep. Smith, Christopher H. [R-NJ-4]

Party: Republican • **State:** NJ • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		Jun 26, 2019
Rep. Axne, Cynthia [D-IA-3]	D · IA		Aug 2, 2019
Rep. Luetkemeyer, Blaine [R-MO-3]	R · MO		Sep 17, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 27, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 4764	Related bill	Dec 14, 2020: Message on Senate action sent to the House.
116 S 4672	Related bill	Sep 23, 2020: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S5835)

Stem Cell Therapeutic and Research Reauthorization Act of 2019

This bill modifies and reauthorizes through FY2024 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also reauthorizes through FY2024 the Stem Cell Therapeutic and Research Act of 2005, which provides for the collection and maintenance of new units of high-quality cord blood.

The bill requires the Advisory Council on Blood Stem Cell Transplantation to convene at least twice per calendar year.

Actions Timeline

- **Jun 27, 2019:** Referred to the Subcommittee on Health.
- **Jun 26, 2019:** Introduced in House
- **Jun 26, 2019:** Referred to the House Committee on Energy and Commerce.